Omega Therapeutics, Inc.
OMGA · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $3,094 | $2,073 | $144 | $0 |
| % Growth | 49.3% | 1,339.6% | – | – |
| Cost of Goods Sold | $65,869 | $5,190 | $1,387 | $1,146 |
| Gross Profit | -$62,775 | -$3,117 | -$1,243 | -$1,146 |
| % Margin | -2,028.9% | -150.4% | -863.2% | – |
| R&D Expenses | $77,169 | $79,996 | $47,865 | $21,063 |
| G&A Expenses | $26,186 | $21,821 | $16,603 | $6,236 |
| SG&A Expenses | $26,186 | $21,821 | $16,603 | $6,236 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3,022 | $1,708 | $1,346 |
| Operating Expenses | $103,355 | $104,839 | $66,176 | $28,645 |
| Operating Income | -$100,261 | -$102,766 | -$66,032 | -$28,645 |
| % Margin | -3,240.5% | -4,957.4% | -45,855.6% | – |
| Other Income/Exp. Net | $2,833 | $65 | -$2,248 | -$802 |
| Pre-Tax Income | -$97,428 | -$102,701 | -$68,280 | -$29,447 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$97,428 | -$102,636 | -$69,162 | -$30,199 |
| % Margin | -3,148.9% | -4,951.1% | -48,029.2% | – |
| EPS | -1.8 | -2.14 | -1.45 | -0.63 |
| % Growth | 15.9% | -47.6% | -130.2% | – |
| EPS Diluted | -1.8 | -2.14 | -1.45 | -0.63 |
| Weighted Avg Shares Out | 54,011 | 47,881 | 47,793 | 47,836 |
| Weighted Avg Shares Out Dil | 54,011 | 47,881 | 47,793 | 47,836 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,810 | $222 | $0 | $777 |
| Interest Expense | $0 | $0 | $910 | $777 |
| Depreciation & Amortization | $6,771 | $5,190 | $1,387 | $1,146 |
| EBITDA | -$93,490 | -$97,576 | -$64,645 | -$27,499 |
| % Margin | -3,021.7% | -4,707% | -44,892.4% | – |